Free Trial

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

-0.42 (-0.62%)
(As of 01:21 PM ET)
Today's Range
50-Day Range
52-Week Range
223,248 shs
Average Volume
881,202 shs
Market Capitalization
$7.16 billion
P/E Ratio
Dividend Yield
Price Target

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
34.6% Upside
$91.50 Price Target
Short Interest
3.79% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.27mentions of Intra-Cellular Therapies in the last 14 days
Based on 9 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.53) to $0.93 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Medical Sector

42nd out of 913 stocks

Pharmaceutical Preparations Industry

16th out of 429 stocks

ITCI stock logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

ITCI Stock News Headlines

ITCI Aug 2024 65.000 put
Intra-Cellular Therapies Inc
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$464.37 million
Book Value
$6.15 per share


Free Float
Market Cap
$7.20 billion
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 71)
    Co-Founder, Chairman & CEO
    Comp: $2.23M
  • Mr. Michael I. Halstead J.D. (Age 51)
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 61)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 73)
    Senior VP & Chief Scientific Officer
    Comp: $646.12k
  • Mr. Juan Fernando Sanchez (Age 53)
    Vice President of Corporate Communications & Investor Relations
    Comp: $296.75k
  • Ms. Karen Patruno Sheehy Esq. (Age 62)
    Senior VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Senior VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Senior VP of Market Access, Policy & Government Affairs
  • Dr. Willie R. Earley M.D.
    Senior VP & Head of Clinical Development

ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price target for 2024?

11 Wall Street analysts have issued 12 month target prices for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $77.00 to $120.00. On average, they predict the company's stock price to reach $91.50 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2024?

Intra-Cellular Therapies' stock was trading at $71.62 on January 1st, 2024. Since then, ITCI shares have decreased by 5.1% and is now trading at $68.00.
View the best growth stocks for 2024 here

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 4,000,000 shares, a decrease of 12.1% from the May 15th total of 4,550,000 shares. Based on an average trading volume of 928,400 shares, the days-to-cover ratio is currently 4.3 days.
View Intra-Cellular Therapies' Short Interest

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our ITCI earnings forecast

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The biopharmaceutical company earned $144.90 million during the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 18.49% and a negative net margin of 21.57%. Intra-Cellular Therapies's quarterly revenue was up 52.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.46) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.53%), Wasatch Advisors LP (3.98%), Bellevue Group AG (2.67%), Avoro Capital Advisors LLC (2.34%), Clearbridge Investments LLC (1.65%) and Price T Rowe Associates Inc. MD (1.14%). Insiders that own company stock include Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam.
View institutional ownership trends

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 6/13/2024 by Staff

From Our Partners